References
Adler SP, Starr SE, Plotkin SA, et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995 Jan; 171: 26–32
Adler SP, Hempflings SH, Starr SE, et al. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 1998 Mar; 17: 200–6
Adler SP, Plotkin SA, Gonczol E, et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 1999 Sep; 180: 843–6
Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial. Ann Intern Med 1991 Apr 1; 114: 525–31
Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994 Dec 15; 58: 1176–8
Adler SP. Development and clinical status of cytomegalovirus vaccines. Clin Immunother 1994 Jul; 2: 1–6
Porath A, McNutt RA, Smiley LM, et al. Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease. Rev Infect Dis 1990 Jan–Feb; 12: 31–40
Rights and permissions
About this article
Cite this article
Cytomegalovirus Vaccine Live (Pasteur Mérieux Connaught). Drugs R&D 2, 310–312 (1999). https://doi.org/10.2165/00126839-199902050-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902050-00006